Most-Upgraded StocksMost-UpgradedNASDAQ:ACAD ACADIA Pharmaceuticals (ACAD) Stock Forecast, Price & News $24.78 +0.33 (+1.35%) (As of 05/26/2023 04:00 PM ET) Add Compare Share Share Today's Range$24.35▼$24.8050-Day Range$17.80▼$25.6552-Week Range$12.24▼$26.04Volume1.21 million shsAverage Volume1.51 million shsMarket Capitalization$4.03 billionP/E RatioN/ADividend YieldN/APrice Target$25.43 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media ACADIA Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.47 Rating ScoreUpside/Downside2.6% Upside$25.43 Price TargetShort InterestBearish6.13% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 15 Articles This WeekInsider TradingAcquiring Shares$5.31 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.56) to ($0.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.84 out of 5 starsMedical Sector778th out of 1,010 stocksPharmaceutical Preparations Industry390th out of 494 stocks 2.2 Analyst's Opinion Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.47, and is based on 10 buy ratings, 5 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.43, ACADIA Pharmaceuticals has a forecasted upside of 2.6% from its current price of $24.78.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.13% of the outstanding shares of ACADIA Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently increased by 3.32%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACAD. Previous Next 2.6 News and Social Media Coverage News SentimentACADIA Pharmaceuticals has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for ACADIA Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 13 people have searched for ACAD on MarketBeat in the last 30 days. This is a decrease of -24% compared to the previous 30 days.MarketBeat Follows7 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have bought 314.91% more of their company's stock than they have sold. Specifically, they have bought $5,312,037.00 in company stock and sold $1,280,295.00 in company stock.Percentage Held by Insiders28.40% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.79% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow in the coming year, from ($0.56) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is -27.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is -27.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 10.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ACADIA Pharmaceuticals (NASDAQ:ACAD) StockACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.Read More Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACAD Stock News HeadlinesMay 27, 2023 | benzinga.comACADIA Pharmaceuticals Stock (NASDAQ:ACAD), Insider Trading ActivityMay 27, 2023 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Trading Down 6.1%May 29, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...May 27, 2023 | americanbankingnews.comResearch Analysts Offer Predictions for ACADIA Pharmaceuticals Inc.'s Q2 2023 Earnings (NASDAQ:ACAD)May 24, 2023 | thestreet.comACADIA Stock Gaps Down On Today's Open (ACAD)May 22, 2023 | msn.comB of A Securities Maintains Acadia Pharmaceuticals (ACAD) Neutral RecommendationMay 22, 2023 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Raised to $26.00 at Bank of AmericaMay 22, 2023 | americanbankingnews.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) COO Sells $334,552.50 in StockMay 29, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...May 22, 2023 | americanbankingnews.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) CFO Sells $344,475.00 in StockMay 20, 2023 | americanbankingnews.comStockNews.com Begins Coverage on ACADIA Pharmaceuticals (NASDAQ:ACAD)May 19, 2023 | msn.comChart of the Day: Acadia PharmaceuticalsMay 18, 2023 | nasdaq.comAcadia Pharmaceuticals Reaches Analyst Target PriceMay 16, 2023 | americanbankingnews.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives $25.40 Consensus Target Price from AnalystsMay 14, 2023 | markets.businessinsider.comThese Biotech Stocks Hit New Highs Last Week - Were You Ahead Of The Game?May 13, 2023 | americanbankingnews.comACADIA Pharmaceuticals Inc. to Post FY2023 Earnings of ($0.65) Per Share, HC Wainwright Forecasts (NASDAQ:ACAD)May 11, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Zentalis Pharmaceuticals (ZNTL)May 11, 2023 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) PT Raised to $23.00 at JMP SecuritiesMay 10, 2023 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Issues Quarterly Earnings ResultsMay 9, 2023 | msn.comCantor Fitzgerald Reiterates Acadia Pharmaceuticals (ACAD) Overweight RecommendationMay 9, 2023 | markets.businessinsider.comACADIA Pharmaceuticals (ACAD) Receives a Buy from Cantor FitzgeraldMay 9, 2023 | markets.businessinsider.comWhat 22 Analyst Ratings Have To Say About ACADIA PharmaceuticalsMay 9, 2023 | markets.businessinsider.comCitigroup Remains a Hold on ACADIA Pharmaceuticals (ACAD)May 9, 2023 | msn.comJMP Securities Maintains Acadia Pharmaceuticals (ACAD) Outperform RecommendationMay 9, 2023 | markets.businessinsider.comACADIA Pharmaceuticals (ACAD) Gets a Buy from H.C. WainwrightMay 9, 2023 | msn.comHC Wainwright & Co. Reiterates Acadia Pharmaceuticals (ACAD) Buy RecommendationMay 9, 2023 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Raised to $21.60See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACAD Company Calendar Last Earnings5/08/2023Today5/29/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACAD CUSIPN/A CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees514Year FoundedN/APrice Target and Rating Average Stock Price Forecast$25.43 High Stock Price Forecast$95.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+2.6%Consensus RatingHold Rating Score (0-4)2.47 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-215,980,000.00 Net Margins-28.05% Pretax Margin-28.03% Return on Equity-35.70% Return on Assets-23.75% Debt Debt-to-Equity RatioN/A Current Ratio2.24 Quick Ratio2.21 Sales & Book Value Annual Sales$517.23 million Price / Sales7.79 Cash FlowN/A Price / Cash FlowN/A Book Value$2.30 per share Price / Book10.77Miscellaneous Outstanding Shares162,630,000Free Float116,440,000Market Cap$4.03 billion OptionableOptionable Beta0.54 Key ExecutivesStephen R. DavisChief Executive Officer & DirectorBrendan P. TeehanChief Operating Officer, EVP & Head-CommercialMark C. SchneyerChief Financial Officer & Executive Vice PresidentPonni SubbiahChief Medical Officer & Senior Vice PresidentSanjeev PathakSenior Vice President & Head-Clinical DevelopmentKey CompetitorsElanco Animal HealthNYSE:ELANTG TherapeuticsNASDAQ:TGTXPTC TherapeuticsNASDAQ:PTCTArrowhead PharmaceuticalsNASDAQ:ARWRPerrigoNYSE:PRGOView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 3,465 shares on 5/26/2023Ownership: 0.016%Bros. Advisors Lp BakerBought 209,053 shares on 5/23/2023Total: $5.31 M ($25.41/share)Capital Impact Advisors LLCBought 1,160 shares on 5/23/2023Ownership: 0.012%Ameriprise Financial Inc.Bought 57,179 shares on 5/22/2023Ownership: 0.357%Putnam Investments LLCSold 1,067 shares on 5/22/2023Ownership: 0.016%View All Insider TransactionsView All Institutional Transactions ACAD Stock - Frequently Asked Questions Should I buy or sell ACADIA Pharmaceuticals stock right now? 17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 2 sell ratings, 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ACAD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares. View ACAD analyst ratings or view top-rated stocks. What is ACADIA Pharmaceuticals' stock price forecast for 2023? 17 brokerages have issued 1 year price objectives for ACADIA Pharmaceuticals' shares. Their ACAD share price forecasts range from $12.00 to $95.00. On average, they predict the company's share price to reach $25.43 in the next twelve months. This suggests a possible upside of 2.6% from the stock's current price. View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts. How have ACAD shares performed in 2023? ACADIA Pharmaceuticals' stock was trading at $15.92 at the beginning of 2023. Since then, ACAD stock has increased by 55.7% and is now trading at $24.78. View the best growth stocks for 2023 here. When is ACADIA Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our ACAD earnings forecast. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its earnings results on Monday, May, 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.06. The biopharmaceutical company had revenue of $118.46 million for the quarter, compared to analysts' expectations of $120.29 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 35.70% and a negative net margin of 28.05%. The firm's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.70) earnings per share. What ETFs hold ACADIA Pharmaceuticals' stock? ETFs with the largest weight of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Dynamic Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings? ACADIA Pharmaceuticals updated its FY 2023 earnings guidance on Monday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $520.00 million-$550.00 million, compared to the consensus revenue estimate of $556.45 million. What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO? 8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL). What is ACADIA Pharmaceuticals' stock symbol? ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD." Who are ACADIA Pharmaceuticals' major shareholders? ACADIA Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Baker BROS. Advisors LP (25.79%), BlackRock Inc. (6.08%), RTW Investments LP (5.07%), FMR LLC (4.84%), State Street Corp (3.44%) and Price T Rowe Associates Inc. MD (2.80%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, Elena Ridloff, James Kihara, Laura Brege, Mark C Schneyer, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ACADIA Pharmaceuticals' stock price today? One share of ACAD stock can currently be purchased for approximately $24.78. How much money does ACADIA Pharmaceuticals make? ACADIA Pharmaceuticals (NASDAQ:ACAD) has a market capitalization of $4.03 billion and generates $517.23 million in revenue each year. The biopharmaceutical company earns $-215,980,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. How many employees does ACADIA Pharmaceuticals have? The company employs 514 workers across the globe. How can I contact ACADIA Pharmaceuticals? ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.acadia-pharm.com. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at ir@acadia-pharm.com, or via fax at 858-558-2872. This page (NASDAQ:ACAD) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.